Arrowhead Pharmaceuticals Advances Plozasiran Study for Hypertriglyceridemia

Arrowhead Pharmaceuticals, Inc. ((ARWR)) announced an update on their ongoing clinical study.

Arrowhead Pharmaceuticals, Inc. is conducting a Phase 3 open-label extension study titled A Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia (SHASTA-10 Study). The study aims to assess the long-term safety and efficacy of Plozasiran in adults with hypertriglyceridemia and severe hypertriglyceridemia, building on previous research to provide more comprehensive data on its effects.

The intervention being tested is Plozasiran, administered as a subcutaneous injection. This drug aims to manage hypertriglyceridemia by reducing triglyceride levels in the blood, potentially offering a new treatment avenue for patients with this condition.

The study follows an interventional design with a single-group model, meaning all participants receive the same treatment without a control group. There is no masking involved, and the primary purpose is treatment-focused, aiming to gather data on the drug’s efficacy and safety over time.

The study officially started on April 9, 2025, with the last update submitted on August 11, 2025. These dates mark the study’s progress and provide a timeline for when initial and updated findings might be expected.

This study update could positively impact Arrowhead Pharmaceuticals’ stock performance by demonstrating ongoing commitment to developing effective treatments for hypertriglyceridemia. Investors may view this as a sign of potential future revenue streams, especially if Plozasiran proves successful. Competitors in the pharmaceutical industry will likely monitor these developments closely, as advancements in treatment options could shift market dynamics.

The SHASTA-10 study is currently recruiting, with further details available on the ClinicalTrials portal.